罗沙司他与重组人促红细胞生成素治疗慢性肾性贫血有效性及安全性比较

Efficacy and safety of Rosalrestat and recombinant human erythropoietin in the treatment of chronic renal anemia

目的 比较罗沙司他与重组人促红细胞生成素治疗慢性肾性贫血的有效性及安全性。方法 回顾性分析北部战区总医院自2020年6月1日至2022年12月31日收治的178例慢性肾病伴贫血患者的临床资料。根据治疗方法不同将患者分入促红素组(n=88)和罗沙司他组(n=90)。促红素组使用重组人促红细胞生成素注射液皮下注射;罗沙司他组口服罗沙司他胶囊。比较两组患者的基线资料,治疗前后的贫血相关指标,以及不良事件发生情况。结果 两组患者基线资料比较,差异无统计学意义(P>0.05)。两组患者治疗前和治疗后贫血相关指标比较,差异均无统计学意义(P>0.05);促红素组患者治疗后的红细胞计数、红细胞压积较治疗前有升高趋势,罗沙司他组患者治疗后的红细胞计数、血红蛋白、红细胞压积较治疗前有升高趋势。根据临床实际情况,两组患者接受了14 d或15~28 d的治疗。两组患者治疗前和治疗14 d后贫血相关指标比较,差异均无统计学意义(P>0.05);两组患者治疗14 d后的红细胞计数、血红蛋白、红细胞压积较治疗前均有升高趋势。两组患者治疗前和治疗15~28 d后的红细胞计数、血红蛋白、红细胞压积比较,差异无统计学意义(P>0.05);促红素组患者治疗15~28 d后的红细胞计数、血红蛋白、红细胞压积较治疗前有升高趋势;罗沙司他组患者治疗15~28 d后的红细胞计数、血红蛋白、红细胞压积高于治疗前,差异有统计学意义(P<0.05)。两组患者不良事件发生率比较,差异无统计学意义(P>0.05)。结论 罗沙司他和重组人促红素均可改善慢性肾性贫血患者的贫血,且罗沙司他治疗效果更优。

Objective To compare the efficacy and safety of Roxastat and recombinant human erythropoietin in the treatment of chronic renal anemia.Methods The clinical data of 178 patients with chronic kidney disease with anemia admitted to General Hospital of Northern Theater Command from June 1,2020 to December 31,2022 were retrospectively analyzed.Patients were divided into erythropoietin group(n=88)and Rosallistat group(n=90)according to treatment.Erythropoietin group was injected subcutaneously with recombinant human erythropoietin injection.Rosalrestat group took Rosalrestat capsules orally.Baseline data,anemia-related indicators before and after treatment,and adverse events were compared between the two groups.Results There was no significant difference in baseline data between the two groups(P>0.05).There was no significant difference in anemia related indexes between the two groups before and after treatment(P>0.05).The red blood cell count and hematocrit in the erythropoietin group after treatment were higher than those before treatment,and the red blood cell count,hemoglobin and hematocrit in the Rosallistat group after treatment were higher than those before treatment.According to the actual clinical situation,the two groups of patients received 14 days or 15 to 28 days of treatment.There was no significant difference in anemia related indexes between the two groups before treatment and 14 days after treatment(P>0.05).After 14 days of treatment,the red blood cell count,hemoglobin and hematocrit of the two groups were higher than those before treatment.There was no significant difference in red blood cell count,hemoglobin and hematocrit between two groups before treatment and 15 to 28 days after treatment(P>0.05).The red blood cell count,hemoglobin and hematocrit in the erythropoietin group after 15 to 28 days of treatment were higher than those before treatment.The red blood cell count,hemoglobin and hematocrit in Roxallistat group after 15 to 28 days of treatment were higher than those before treatment,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05).Conclusion Both Roxallistat and recombinant human erythropoietin can improve anemia in patients with chronic renal anemia,and Roxallistat is more effective in treatment.